Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma (Q33374964)

26 July 2017

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma (English)

1 reference

26 July 2017

1 reference

9

Sagar Lonial

1 reference

26 July 2017

12

Kenneth C Anderson

1 reference

26 July 2017

2

Pieter Sonneveld

1 reference

26 July 2017

6

Thierry Facon

1 reference

26 July 2017

1

Paul G Richardson

1 reference

26 July 2017

5

Edward A Stadtmauer

1 reference

26 July 2017

7

Jean-Luc Harousseau

1 reference

26 July 2017

11

Jamie D Cavenagh

1 reference

26 July 2017

Michael W Schuster

3

1 reference

26 July 2017

David Irwin

series ordinal

4

1 reference

26 July 2017

Dina Ben-Yehuda

series ordinal

8

1 reference

26 July 2017

Jesús-F San Miguel

series ordinal

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

19 April 2007

1 reference

British Journal of Haematology

26 July 2017

1 reference

26 July 2017

137

1 reference

26 July 2017

5

1 reference

26 July 2017

429-435

1 reference

Treatment of multiple myeloma in elderly people: long-term results in 178 patients

26 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06585.X

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06585.X

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06585.X

A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06585.X

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06585.X

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06585.X

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06585.X

The adverse prognostic impact of advanced age in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06585.X

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06585.X

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06585.X

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06585.X

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06585.X

10.1111/J.1365-2141.2007.06585.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference